Project Grant R44AI188967
Award Date 8/1/25
Completion Date 7/31/28
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,182,827 Project Grant to Duke University to develop a 3D bioprinted alveolar sac model and dual host-microbe spatial transcriptomics technology. The goal is to enhance understanding of how the lung microbiome regulates the host response to influenza virus infection. This Allergy and Infectious Diseases Research (CFDA 93.855) program grant will fund the creation of innovative in vitro technologies to study interactions...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,937,578 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Chapel Hill. The grant, awarded on August 18, 2025, supports the development of an ACE2 immunodecoy therapy for long-lasting immunoprophylaxis against SARS-CoV-2 variants and other zoonotic coronaviruses that target the human ACE2 receptor. The project aims to optimize the linkage...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a broad-spectrum influenza vaccine. The project aims to evaluate recently discovered neuraminidase broadly neutralizing antibodies (NA BNAbs) and engineer NA immunogens that can engage diverse BNAb precursors, a strategy called germline targeting. This protein engineering effort...
- This $3,170,096 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to develop the L7AE protein as a therapeutic for treating infections caused by the Orthomyxoviridae virus family, which includes influenza. The key research aims are: (1) investigating the mechanism of action of L7AE on various Orthomyxoviridae family members, (2)...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,323,410 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to Georgia State University Research Foundation Inc. to advance the development of inhibitors targeting seasonal and pandemic influenza viruses. The project aims to progress preclinical development and assemble an investigational new drug package for oral antiviral therapeutics, including a novel pyrimidine...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,013,468 to Inhalon Biopharma, Inc. to advance the development of IN-003PI, a passive immunization treatment against human metapneumovirus (MPV) infections. The funding will support key research activities such as producing GLP-compliant antibody batches, conducting IND-enabling toxicology and efficacy studies, and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,004,473 Project Grant to Autonomous Therapeutics Inc. under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports the development of a new class of "encrypted RNA" (EncRNA) antiviral therapeutics that can target SARS-CoV-2 variants and potentially other RNA viruses. The lead candidate, AT191, is designed to be self-administered and prevent hospitalizations or deaths by...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,968 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Viva Viral Vaccines, Inc. to develop a broad-spectrum, multivalent vaccine platform for pandemic and seasonal influenza. The platform leverages innovations in the production of influenza neuraminidase (NA) proteins in mammalian cells, enabling the development of VLP-based vaccines that can provide broad heterologous...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $292,746 Cooperative Agreement to Tsrl, Inc. (doing business as Therapeutic Systems Research Laboratories), a woman-owned small business located in Ann Arbor, Michigan. The purpose of this award is to conduct a Phase 1 clinical trial to assess the pharmacokinetics, safety, and tolerance of a zanamivir transdermal system in healthy subjects. This...